Scenarios that move LLY
Eli Lilly and Company Common Stock
Scenarios that move LLY: 23 analyses, 11 positive, 12 negative.
- · ◇ What if… Indiana enacts data center moratorium by June 30, 2027 — ▲ · impact +25 · confidence low · horizon quarters
- · J&J beats Q3 earnings estimates, misses sales and raises outlook — ▲ · impact +65 · confidence low · horizon quarters
- · Viking Therapeutics advances oral obesity drug to Phase III — ▼ · impact -48 · confidence high · horizon quarters
- · Hims & Hers faces securities fraud class action after FTC lawsuit — ▲ · impact +39 · confidence medium · horizon quarters
- · Viatris to acquire Pacira for $1.65B in pain portfolio deal — ▲ · impact +8 · confidence low · horizon quarters
- · Spyre Therapeutics prices $350 million public stock offering — ▼ · impact -6 · confidence low · horizon quarters
- · Liquidia stock plunges 57% after UTHR patent setback — ▲ · impact +15 · confidence low · horizon quarters
- · Zealand Pharma reports positive survodutide Phase III weight loss results — ▼ · impact -46 · confidence high · horizon quarters
- · Novo Nordisk's Ozempic outperforms Lilly's Mounjaro on cardiovascular risk — ▼ · impact -85 · confidence high · horizon immediate
- · Lilly reports strong weight loss results for new drug — ▲ · impact +94 · confidence medium · horizon immediate
- · Novo and Hengrui sign exclusive license for oral GLP-1/GIP drug — ▼ · impact -48 · confidence high · horizon quarters
- · Zymeworks updates 2026 guidance after Theravance acquisition — ▼ · impact -30 · confidence low · horizon quarters
- · Beta Bionics stock plunges 37% after safety issues emerge — ▲ · impact +35 · confidence low · horizon quarters
- · Pharma stock soars 150% after injectables deal with Novo — ▼ · impact -55 · confidence high · horizon quarters
- · Ionis reports positive late-stage results for two partnered drugs — ▼ · impact -24 · confidence low · horizon quarters
- · ◇ What if… Oral GLP-1 drugs replace injectable treatments — ▲ · impact +68 · confidence medium · horizon quarters
- · Oruka Therapeutics reports positive week 28 ORKA-001 trial data — ▼ · impact -25 · confidence high · horizon quarters
- · Viking Therapeutics stock skyrockets in Tuesday trading — ▼ · impact -51 · confidence medium · horizon weeks
- · ◇ What if… Xavier Becerra wins California’s 2026 governor election — ▼ · impact -26 · confidence low · horizon quarters
- · Beta Bionics prices public offering of stock and warrants — ▲ · impact +6 · confidence low · horizon quarters
- · AstraZeneca's Etcamah fails late-stage study in first-line breast cancer — ▲ · impact +30 · confidence high · horizon quarters
- · Amgen shares fall after Novartis' Pelacarsen misses Phase III goal — ▼ · impact -24 · confidence medium · horizon immediate
- · Eli Lilly Weight Loss Pill Shows Better Results Than Injectable Competitors In Phase 3 Trial — ▲ · confidence medium